Feedback / Questions
MK-6105 - Merck (MSD), CSL Behring
http://www.globenewswire.com/news-release/2019/06/04/1863879/0/en/ASLAN-Pharmaceuticals-Completes-Phase-1-Study-for-ASLAN004-Targeting-Atopic-Dermatitis.html
Jun 4, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next